Drug resistant cSrc kinase domain in complex with inhibitor RL45 (Type II)

Drug resistant cSrc kinase domain in complex with inhibitor RL45 (Type II) Descriptor: 1-{4-[(6-aminoquinazolin-4-yl)amino]phenyl}-3-[3-tert-butyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]urea, Proto-oncogene tyrosine-protein kinase Src Authors: Grutter, C, Kluter, S, Getlik, M, Rauh, D. Deposit date: 2008-10-31 Release date: 2009-06-02 Last modified: 2023-11-01 Method: X-RAY DIFFRACTION (2.6 Å) Cite: Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc J.Med.Chem., 52, 2009与II型抑制剂RL45结合的耐药性cSrc激酶结构域 描述：1-{4-[(6-氨基喹唑啉-4-基)氨基]苯基}-3-[3-叔丁基-1-(3-甲基苯基)-1H-吡唑-5-基]脲，原癌基因酪氨酸蛋白激酶Src 作者：Grutter C、Kluter S、Getlik M、Rauh D 沉积日期：2008-10-31 发布日期：2009-06-02 最后修改日期：2023-11-01 实验方法：X射线衍射（分辨率2.6 Å） 引用文献：《克服cSrc守门人T338M突变的杂合化合物设计》，《药物化学杂志》（J.Med.Chem.），第52卷，2009年